We have located links that may give you full text access.
JOURNAL ARTICLE
OBSERVATIONAL STUDY
All-Cause and Cause-Specific Mortality in Patients With Granulomatosis With Polyangiitis: A Population-Based Study.
Arthritis Care & Research 2019 January
OBJECTIVE: To investigate all-cause and cause-specific mortality in patients with newly diagnosed granulomatosis with polyangiitis (GPA) between 2 calendar time periods, 1997-2004 and 2005-2012.
METHODS: Using an administrative health database, we compared all patients with incident GPA with non-GPA controls matched for sex, age, and time of entry into the study. The study cohorts were divided into 2 subgroups based on the year of diagnosis ("early cohort [1997-2004] and "late cohort" [2005-2012]). The outcome was death (all-cause, cardiovascular disease [CVD]-related cancer-related, renal disease-related, and infection-related) during the follow-up period. Hazard ratios (HR) were estimated using Cox proportional hazards models, first adjusted for age, sex, and time of entry and then adjusted for selected covariates based on a purposeful selection algorithm.
RESULTS: Three hundred seventy patients with GPA and 3,700 non-GPA controls were included in this study, contributing 1,624.8 and 1,8671.3 person-years of follow-up, respectively. Sixty-eight deaths occurred in the GPA cohort, and 310 deaths occurred in the non-GPA cohort. Overall, the age-, sex-, and entry time-adjusted all-cause mortality HR in the GPA cohort was 3.12 (95% confidence interval CI 2.35-4.14). There was excess mortality due to CVD-related causes, but not cancer, in the GPA cohort. Reports of death due to infection or renal disease was not permitted, because the numbers of death were insufficient (<6 deaths for each outcome). All-cause mortality significantly improved between the early cohort and late cohort time periods (HR 5.61 and 2.33, respectively; P for interaction = 0.017).
CONCLUSION: This population-based study showed increased all-cause and CVD-related mortality risks in patients with GPA. There was significant improvement in the all-cause mortality risk over time, but the risk remained increased compared with that in the general population.
METHODS: Using an administrative health database, we compared all patients with incident GPA with non-GPA controls matched for sex, age, and time of entry into the study. The study cohorts were divided into 2 subgroups based on the year of diagnosis ("early cohort [1997-2004] and "late cohort" [2005-2012]). The outcome was death (all-cause, cardiovascular disease [CVD]-related cancer-related, renal disease-related, and infection-related) during the follow-up period. Hazard ratios (HR) were estimated using Cox proportional hazards models, first adjusted for age, sex, and time of entry and then adjusted for selected covariates based on a purposeful selection algorithm.
RESULTS: Three hundred seventy patients with GPA and 3,700 non-GPA controls were included in this study, contributing 1,624.8 and 1,8671.3 person-years of follow-up, respectively. Sixty-eight deaths occurred in the GPA cohort, and 310 deaths occurred in the non-GPA cohort. Overall, the age-, sex-, and entry time-adjusted all-cause mortality HR in the GPA cohort was 3.12 (95% confidence interval CI 2.35-4.14). There was excess mortality due to CVD-related causes, but not cancer, in the GPA cohort. Reports of death due to infection or renal disease was not permitted, because the numbers of death were insufficient (<6 deaths for each outcome). All-cause mortality significantly improved between the early cohort and late cohort time periods (HR 5.61 and 2.33, respectively; P for interaction = 0.017).
CONCLUSION: This population-based study showed increased all-cause and CVD-related mortality risks in patients with GPA. There was significant improvement in the all-cause mortality risk over time, but the risk remained increased compared with that in the general population.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app